K

Kaken Pharmaceutical Co Ltd
TSE:4521

Watchlist Manager
Kaken Pharmaceutical Co Ltd
TSE:4521
Watchlist
Price: 4 376 JPY 0.3% Market Closed
Market Cap: 165.7B JPY
Have any thoughts about
Kaken Pharmaceutical Co Ltd?
Write Note

Kaken Pharmaceutical Co Ltd
Net Income

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

Kaken Pharmaceutical Co Ltd
Net Income Peer Comparison

Comparables:
4502
4568
4578
4519
4503

Competitive Net Income Analysis
Latest Figures & CAGR of Competitors

Company Net Income CAGR 3Y CAGR 5Y CAGR 10Y
K
Kaken Pharmaceutical Co Ltd
TSE:4521
Net Income
ÂĄ9.8B
CAGR 3-Years
-19%
CAGR 5-Years
-17%
CAGR 10-Years
-4%
Takeda Pharmaceutical Co Ltd
TSE:4502
Net Income
ÂĄ150.1B
CAGR 3-Years
-30%
CAGR 5-Years
71%
CAGR 10-Years
3%
Daiichi Sankyo Co Ltd
TSE:4568
Net Income
ÂĄ295.3B
CAGR 3-Years
55%
CAGR 5-Years
21%
CAGR 10-Years
9%
Otsuka Holdings Co Ltd
TSE:4578
Net Income
ÂĄ146B
CAGR 3-Years
-9%
CAGR 5-Years
4%
CAGR 10-Years
-4%
Chugai Pharmaceutical Co Ltd
TSE:4519
Net Income
N/A
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Astellas Pharma Inc
TSE:4503
Net Income
ÂĄ28.6B
CAGR 3-Years
-38%
CAGR 5-Years
-36%
CAGR 10-Years
-15%

See Also

What is Kaken Pharmaceutical Co Ltd's Net Income?
Net Income
9.8B JPY

Based on the financial report for Jun 30, 2024, Kaken Pharmaceutical Co Ltd's Net Income amounts to 9.8B JPY.

What is Kaken Pharmaceutical Co Ltd's Net Income growth rate?
Net Income CAGR 10Y
-4%

Over the last year, the Net Income growth was 44%. The average annual Net Income growth rates for Kaken Pharmaceutical Co Ltd have been -19% over the past three years , -17% over the past five years , and -4% over the past ten years .

Back to Top